Cyclic AMP- and (Rp)-cAMPS-induced Conformational Changes in a Complex of the Catalytic and Regulatory (RI{alpha}) Subunits of Cyclic AMP-dependent Protein Kinase
Overview
Cell Biology
Molecular Biology
Authors
Affiliations
We took a discovery approach to explore the actions of cAMP and two of its analogs, one a cAMP mimic ((S(p))-adenosine cyclic 3':5'-monophosphorothioate ((S(p))-cAMPS)) and the other a diastereoisomeric antagonist ((R(p))-cAMPS), on a model system of the type Iα cyclic AMP-dependent protein kinase holoenzyme, RIα(91-244)·C-subunit, by using fluorescence spectroscopy and amide H/(2)H exchange mass spectrometry. Specifically, for the fluorescence experiments, fluorescein maleimide was conjugated to three cysteine single residue substitution mutants, R92C, T104C, and R239C, of RIα(91-244), and the effects of cAMP, (S(p))-cAMPS, and (R(p))-cAMPS on the kinetics of R-C binding and the time-resolved anisotropy of the reporter group at each conjugation site were measured. For the amide exchange experiments, ESI-TOF mass spectrometry with pepsin proteolytic fragmentation was used to assess the effects of (R(p))-cAMPS on amide exchange of the RIα(91-244)·C-subunit complex. We found that cAMP and its mimic perturbed at least parts of the C-subunit interaction Sites 2 and 3 but probably not Site 1 via reduced interactions of the linker region and αC of RIα(91-244). Surprisingly, (R(p))-cAMPS not only increased the affinity of RIα(91-244) toward the C-subunit by 5-fold but also produced long range effects that propagated through both the C- and R-subunits to produce limited unfolding and/or enhanced conformational flexibility. This combination of effects is consistent with (R(p))-cAMPS acting by enhancing the internal entropy of the R·C complex. Finally, the (R(p))-cAMPS-induced increase in affinity of RIα(91-244) toward the C-subunit indicates that (R(p))-cAMPS is better described as an inverse agonist because it decreases the fractional dissociation of the cyclic AMP-dependent protein kinase holoenzyme and in turn its basal activity.
Lorigo M, Oliveira N, Cairrao E J Cardiovasc Dev Dis. 2022; 9(1).
PMID: 35050214 PMC: 8777754. DOI: 10.3390/jcdd9010004.
Allosteric inhibition explained through conformational ensembles sampling distinct "mixed" states.
Byun J, VanSchouwen B, Akimoto M, Melacini G Comput Struct Biotechnol J. 2020; 18:3803-3818.
PMID: 33335680 PMC: 7720024. DOI: 10.1016/j.csbj.2020.10.026.
Allosteric pluripotency as revealed by protein kinase A.
Byun J, Akimoto M, VanSchouwen B, Lazarou T, Taylor S, Melacini G Sci Adv. 2020; 6(25):eabb1250.
PMID: 32596469 PMC: 7304965. DOI: 10.1126/sciadv.abb1250.
Oz S, Pankonien I, Belkacemi A, Flockerzi V, Klussmann E, Haase H J Physiol. 2017; 595(10):3181-3202.
PMID: 28194788 PMC: 5430219. DOI: 10.1113/JP274015.
Ligand-mediated changes in conformational dynamics of NpmA: implications for ribosomal interactions.
Husain N, Tulsian N, Chien W, Suresh S, Anand G, Sivaraman J Sci Rep. 2016; 6:37061.
PMID: 27845431 PMC: 5109232. DOI: 10.1038/srep37061.